Nutrition and cardiac cachexia

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 9, Issue 1, 2006, Pages 18-23

  Azhar, Gohar ^a   Wei, Jeanne Y ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Cachexia; Gut; Heart failure; Inflammation; Muscle atrophy; Nutrition

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CURCUMIN; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTOXIN; FISH OIL; GREEN TEA EXTRACT; LINSEED OIL; LIPOPROTEIN; MUSCLE PROTEIN; OLIVE OIL; OMEGA 3 FATTY ACID; S ADENOSYLMETHIONINE; THIOCTIC ACID; UBIDECARENONE;

ATHEROSCLEROSIS; CACHEXIA; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; DEATH; DIET SUPPLEMENTATION; DIET THERAPY; DISEASE ASSOCIATION; ELECTROLYTE INTAKE; EXERCISE; FLUID THERAPY; GASTROINTESTINAL TRACT; HEALTH CARE PERSONNEL; HUMAN; INFLAMMATION; LIPID METABOLISM; LIPID OXIDATION; LONG TERM CARE; MUSCLE ATROPHY; NEUROENDOCRINE SYSTEM; NUTRITION; PHYSICAL ACTIVITY; PROGNOSIS; PROTEIN DEPLETION; REVIEW; WEIGHT REDUCTION; AGED; FEMALE; MALE; PATHOPHYSIOLOGY; PHYSIOLOGY;

AGED; CACHEXIA; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; NUTRITION PHYSIOLOGY;

EID: 33646257568     PISSN: 13631950     EISSN: 15353885     Source Type: Journal    
DOI: 10.1097/01.mco.0000198060.10991.50     Document Type: Review

References (52)

1. Wei JY. Congestive heart failure. In: Abrams WB, Berkow R, editors. Merck Manual of Geriatrics, 2nd ed. West Point, Pennsylvania: Merck & Co; 1995. pp. 513-522.
2. Goldberg RJ, Spencer FA, Farmer C, et al. Incidence and hospital death rates associated with heart failure: a community-wide perspective. Am J Med 2005; 118:728-734.
3. Forman DE, Wei JY. Congestive heart failure in the elderly. In: Sheehan MN, Wei JY, editors. Geriatric Medicine: a case-based manual. New York: Oxford University Press; 1997. pp. 67-79.
4. Pugh KG, Wei JY. Clinical implications of physiological changes in the aging heart. Drugs Aging 2001; 18:263-276.
5. Filippatos GS, Anker SD, Kremastinos DT. Pathophysiology of peripheral muscle wasting in cardiac cachexia. Curr Opin Clin Nutr Metab Care 2005; 8:249-254. An exellent and comprehensive review of the various mechanisms whereby skeletal muscle wasting in cardiac cachexia may occur. It ties together the findings of many cytokine-activation and muscle atrophy studies.
6. Strassburg S, Springer J, Anker SD. Muscle wasting in cardiac cachexia. Int J Biochem Cell Biol 2005; 37:1938-1947. This paper summarizes the complex changes that lead to cardiac cachexia, a serious complication of chronic heart failure, which is a catabolic/anabolic imbalance resulting in body wasting and has a poor prognosis characterized by a wasting process that affects all body components.
7. Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 1990; 323:236-241.
8. Wei JY. Age and the cardiovascular system. N Engl J Med 1992; 327:1735-1739.
9. Samuel RS, Hausdorff J, Wei JY. Congestive heart failure with preserved systolic function: is it a woman's disease? Womens Health Issues 1999; 9:219-222.
10. Odiet JA, Wei JY. Heart failure and the aging myocardium. Heart Fail Rev 1996; 2:139-149.
11. Kyne L, Hausdorff JM, Knight E, et al. Neutrophilia and congestive heart failure following acute myocardial infarction. Am Heart J 2000; 139:94-100.
12. Tenenbaum A, Fisman EZ. Impaired glucose metabolism in patients with heart failure: pathophysiology and possible treatment strategies. Am J Cardiovasc Drugs 2004; 4:269-280. This review provides an excellent overview of the multifactorial interrelationships among heart failure and diabetes mellitus, lack of physical activity, hypermetabolic state, insulin resistance, intracellular metabolic defects, poor muscle perfusion, and poor nutrition.
13. Krack A, Sharma R, Figulla HR, Anker SD. The importance of the gastrointestinal system in the pathogenesis of heart failure. Eur Heart J 2005; 26:2368-2374. This excellent review discusses the involvement of the gastrointestinal system in CHF. Decreased cardiac function can reduce bowel perfusion and impair the functioning of the intestinal barrier. A 'leaky' bowel wall may in turn lead to translocation of bacteria and/or endotoxin-induced inflammatory cytokine activation in CHF, and may also contribute to malnutrition and cachexia in CHF.
14. Schulze PC, Spate U. Insulin-like growth factor-1 and muscle wasting in chronic heart failure. Int J Biochem Cell Biol 2005; 37:2023-2035. Chronic heart failure in advanced stages may lead to muscle wasting and cachexia accompanied by increased expression of proinflammatory cytokines, increased apoptosis and activation of the proteolytic ubiquitin-proteasome pathway.
15. Hausdorff JM, Forman DE, Ladin Z, et al. Increased walking variability in elderly persons with congestive heart failure. J Am Geriatr Soc 1994; 42:1056-1061.
16. American Heart Association. Heart Disease and Stroke Statistics - 2003 Update. Dallas: American Heart Association; 2002. p. 31.
17. McMurray JJ, Stewart S, Epidemiology, etiology, and prognosis of heart failure. Heart 2000; 83:596-602.
18. Wei JY. Understanding the aging cardiovascular system. Geriatr Gerontol Int 2004; 4:S298-S303.
19. Genth-Zotz S, Bolger AP, Kalra PR, et al. Heat shock protein 70 in patients with chronic heart failure: relation to disease severity and survival. Int J Cardiol 2004; 96:397-401. This paper reports that chronic heart failure is associated with systemic inflammation, particularly in patients with cardiac cachexia. Hsp70 levels are elevated particularly in CHF patients with cardiac cachexia; Hsp70 relates to disease severity.
20. Gabai VL, Meriin AB, Yagblom JA, et al. Suppression of stress kinase JNK is involved in HSP72-mediated protection of myogenic cells from transient energy deprivation. J Biol Chem 2000; 275:38088-38094.
21. Van Beneden R, Gurne O, Selvais PL, et al. Superiority of big endothelin-1 and endothelin-1 over natriuretic peptides in predicting survival in severe congestive heart failure: a 7-year follow-up study. J Card Fail 2004; 10:490-495.
22. Nielsen OW, Rasmussen V, Christensen NJ, Hansen JF. Neuroendocrine testing in community patients with heart disease: plasma N-terminal proatrial natriuretic peptide predicts morbidity and mortality stronger than catecholamines and heart rate variability. Scand J Clin Lab Invest 2004; 64:619-628.
23. Anker SD, Steinborn W, Strassburg S. Cardiac cachexia. Ann Med 2004; 36:518-529. This comprehensive review discusses data which show that cardiac cachexia, a general loss of fat tissue, lean tissue, and bone tissue, is a multifactorial, neuroendocrine, metabolic, and immune disorder with a poor prognosis, independently of functional disease severity, age, and measures of exercise capacity and cardiac function.
24. Florea VG, Moon J, Pennell DJ, et al. Wasting of the left ventricle in patients with cardiac cachexia: a cardiovascular magnetic resonance study. Int J Cardiol 2004; 97:15-20. A significant decrease in left-ventricle mass occurs in patients with cardiac cachexia. This study documents in vivo the wasting of the left ventricle in CHF patients with general body wasting.
25. Castillo-Martinez L, Orea-Tejeda A, Resales MT, et al. Anthropometric variables and physical activity as predictors of cardiac cachexia. Int J Cardiol 2005; 99:239-245. This study evaluated anthropometric variables as predictors of cachexia development in CHF patients. Cardiac cachexia development was not related to low energy intake or increased total energy expenditure; it was only related to lower physical activity.
26. Song YH, Li Y, Du J. Anthropometric variables and physical activity as predictors of cardiac cachexia. Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. J Clin Invest 2005; 115:451-458.
27. Libera LD, Vescovo G. Muscle wastage in chronic heart failure, between apoptosis, catabolism and altered anabolism: a chimaeric view of inflammation? Curr Opin Clin Nutr Metab Care 2004; 7:435-441. The complex mechanisms involved in determining skeletal muscle wastage and cachexia in heart failure include inflammation, the catabolic/anabolic imbalance, and apoptosis.
28. Kalantar-Zadeh K, Block G, Horwich T, Fonarow GC. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol 2004; 43:1439-1444. This report discusses that fact that traditional risk factors of a poor clinical outcome and mortality in the general population also relate to outcome in patients with chronic heart failure, but in an opposite direction. Obesity, hypercholesterolemia, and higher normotensive values of systolic blood pressure (>111 mmHg) have been demonstrated to be associated with greater survival among chronic heart failure patients.
29. Cioffi G, Tarantini L, De Feo S, et al. Functional mitral regurgitation predicts 1-year mortality in elderly patients with systolic chronic heart failure. Eur J Heart Fail 2005; 7:1040-1048.
30. le Roux CW, Ghatei MA, Gibbs JS, Bloom SR. The putative satiety hormone PYY is raised in cardiac cachexia associated with primary pulmonary hypertension. Heart 2005; 91:241-242.
31. Shannon RP, Wei JY, Rosa RM, et al. The effect of age and sodium depletion on cardiovascular response to orthostasis. Hypertension 1986; 8:438-443.
32. Mozaffarian D, Bryson CL, Lemaitre RN, et al. Fish intake and risk of incident heart failure. J Am Coll Cardiol 2005; 45:2015-2021. Among older adults, consumption of tuna or other broiled or baked fish, but not fried fish, is associated with lower incidence of CHF.
33. Coats AJ. Advances in the non-drug, non-surgical, non-device management of chronic heart failure. Int J Cardiol 2005; 100:1-4. This excellent review discusses recent advances in management of heart-failure patients using non-drug, non-surgical, non-device approaches. Nutrition, education, lifestyle interventions, physiotherapy, psychotherapy, and therapies for sleep-disordered breathing have all demonstrated considerable promise in improving care of CHF patients.
34. Pasini E, Opasich C, Pastoris O, Aquilani R. Inadequate nutritional intake for daily life activity of clinically stable patients with chronic heart failure. Am J Cardiol 2004; 93:41A-43A.
35. Houston MC. Nutraceuticals, vitamins, antioxidants, and minerals in the prevention and treatment of hypertension. Prog Cardiovasc Dis 2005; 47:396-449.
36. Colin Ramirez E, Castillo Martinez L, Orea Tejeda A, et al. Effects of a nutritional intervention on body composition, clinical status, and quality of life in patients with heart failure. Nutrition 2004; 20:890-895.
37. Gums JG. Magnesium in cardiovascular and other disorders. Am J Health Syst Pharm 2004; 61:1569-1576. This review discusses the importance of dietary magnesium, and its role in over 300 enzymatic reactions that are involved in energy metabolism, glucose utilization, protein synthesis, fatty acid synthesis and breakdown, ATPase functions, and virtually all hormonal reactions. Magnesium is involved with sodium, potassium, and calcium in maintaining cellular ionic balance.
38. Wood N, Johnson RB. The relationship between tomato intake and congestive heart failure risk in periodontitis subjects. J Clin Periodontol 2004; 31:574-580. This paper reports significant inverse dose-dependent relationships between serum lycopene and C-reactive protein, and monthly tomato consumption and white blood cell count in periodontitis subjects.
39. Fung TT, McCullough ML, Newby PK, et al. Diet-quality scores and plasma concentrations of markers of inflammation and endothelial dysfunction. Am J Clin Nutr 2005; 82:163-173. Diet-quality scores on the Healthy Eating Index and the alternate Mediterranean Diet Index were calculated by using a food-frequency questionnaire. Higher scores on these scales were associated with lower concentrations of biomarkers of inflammation and endothelial dysfunction.
40. King DE, Mainous AG III, Geesey ME, Woolson RF. Dietary magnesium and C-reactive protein levels. J Am Coll Nutr 2005; 24:166-171. Recent evidence from animal and clinical studies suggests that magnesium may be associated with inflammatory processes. Individuals with magnesium intakes below the recommended daily allowance are more likely to have elevated C-reactive protein, which may contribute to cardiovascular disease risk.
41. Jenkins DJ, Kendall CW, Marchie A, et al. RDA. Direct comparison of dietary portfolio vs statin on C-reactive protein. Eur J Clin Nutr 2005; 59:851-860. A combination of cholesterol-lowering foods significantly reduced C-reactive protein to a similar extent as the starting dose of a first-generation statin
42. King DE. Dietary fiber, inflammation, and cardiovascular disease. Mol Nutr Food Res 2005; 49:594-600. This review discusses the evidence for the connections among inflammation, C-reactive protein, dietary fiber, and cardiovascular disease, and recommends future studies using fiber supplementation to isolate and prospectively confirm these important relationships.
43. Rakel DP, Rindfleisch A. Inflammation: nutritional, botanical, and mind-body influences. South Med J 2005; 98:303-310.
44. Ford ES, Mokdad AH. Healthy Eating Index and C-reactive protein concentration: findings from the National Health and Nutrition Examination Survey III, 1988-1994. Eur J Clin Nutr 2005; 59:278-283. After adjustment for age, sex, race or ethnicity, education, smoking status, creatinine concentration, body mass index, waist/hip ratio, aspirin use, alcohol use, physical activity level, and energy intake, the Healthy Eating Index score was inversely associated with an elevated C-reactive protein in logistic regression analysis.
45. Wei JY. Nutrition screening can change your life. Aging Arkansan 2003; 16:4.
46. Robinson JG, Maheshwari N. A "poly-portfolio" for secondary prevention: a strategy to reduce subsequent events by up to 97% over five years. Am J Cardiol 2005; 95:373-378. This report reviewed the projected effects of combinations of a high-dose statin, low to standard doses of antihypertensive therapy, aspirin, omega-3 fish oil, cardiac rehabilitation, and diet on risk of chronic heart disease. Patients with chronic heart disease, myocardial infarction, or stroke were projected to experience 84, 91, and 77% reductions, respectively, in chronic heart disease events from a pharmacologic approach.
47. Mozaffarian D, Longstreth WT Jr, Lemaitre RN, et al. Fish consumption and stroke risk in elderly individuals: the cardiovascular health study. Arch Intern Med 2005; 165:200-206. Among elderly individuals, consumption of tuna or other broiled or baked fish is associated with lower risk of ischemic stroke, while intake of fried fish or fish sandwiches is associated with higher risk. Fish consumption may influence stroke risk late in life.
48. Hausdorff JM, Clark BA, Shannon RP, et al. Hypotensive response to atrial natriuretic peptide administration is enhanced with age. J Gerontol 1995; 50:M169-M172.
49. Kjaer A, Hildebrandt P, Appel J, Petersen CL. Neurohormones as markers of right- and left-sided cardiac dimensions and function in patients with untreated chronic heart failure. Int J Cardiol 2005; 99:301-306. Brain natriuretic peptide reflects the left-ventricular ejection fraction as well as diastolic and systolic dimensions; epinephrine reflects the right-ventricular systolic and diastolic dimensions; and atrial natriuretic peptide reflects the lung transit time. Therefore 'neuroendocrine profiling' may potentially be of diagnostic and therapeutic use.
50. Hogenhuis J, Voors AA, Jaarsma T, et al. Influence of age on natriuretic peptides in patients with chronic heart failure: a comparison between ANP/ NT-ANP and BNP/NT-proBNP. Eur J Heart Fail 2005; 7:81-86.
51. Nielsen OW, Rasmussen V, Christensen NJ, Hansen JF. Neuroendocrine testing in community patients with heart disease: plasma N-terminal proatrial natriuretic peptide predicts morbidity and mortality stronger than catecholamines and heart rate variability. Scand J Clin Lab Invest 2004; 64:619-628. On multivariate analyses, it was found that plasma N-terminal atrial natriuretic peptide and premature ventricular contractions were associated with clinical signs of CHF, echocardiographic cardiac dysfunction, and mortality. Plasma N-terminal atrial natriuretic peptide was stronger than catecholamines and variables of 24 h monitoring (blood pressure and electrocardiogram) in predicting morbidity and mortality in these patients.
52. Birkenfeld AL, Boschmann M, Moro C, et al. Lipid mobilization with physiological atrial natriuretic peptide concentrations in humans. J Clin Endocrinol Metab 2005; 90:3622-3628. Atrial natriuretic peptide stimulates lipid mobilization and oxidation at plasma concentrations that are encountered in conditions such as heart failure.